AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|
27.2 C
New York
Sunday, June 21, 2026

Tag: actions

newssourceFORcompanyinformationcontent1marketreleases

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CALX

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

Expanding its partnership with non-profits, EZVIZ upgrades its Green Initiative to make a true impact on harmony between humans and nature with a week-long...

HOOFDDORP, Netherlands, June 8, 2026 /PRNewswire/ -- EZVIZ, a world-leading smart home brand, announced to enter a new chapter of its EZVIZ Green Initiative by expanding...

Vi Appoints Spencer Honeyman as President, Global Growth

NEW YORK, June 7, 2026 /PRNewswire/ -- Vi today announced the promotion of Spencer Honeyman to President, Global Growth. ...

Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsActions

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers